Cardinal Health Inc
CAH: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|<> | LOCK|#qT<Y | LOCK|?^ZJPW |
Cardinal's Growth Momentum Looks Strong From Prescription Trends, Specialty Investments, and GLP-1s
Business Strategy and Outlook
Cardinal Health is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $200 billion in annual US drug distribution sales in fiscal 2025, Cardinal supplies roughly one-fourth of the overall market. Its two closest competitors are Cencora and McKesson, and together they operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market.
